Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 9/20 | 0.61 |
| ▸ | REN | P00797 | 4/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | F2 | P00734 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | LTA4H | P09960 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | PEPD | P12955 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.55 |
| ▸ | HTR2A | P28223 | 1/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.55 |
| ▸ | HRH1 | P35367 | 1/20 | 0.55 |
| ▸ | THPO | P40225 | 1/20 | 0.55 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11562059 | 0.89 | ACE (0.64) | ACERENRAB9AKDM4EF2 | |
| SCHEMBL5654346 | 0.88 | ACE (0.56) | ACERENRAB9AKDM4EF2 | |
| SCHEMBL17378268 | 0.87 | ACE (0.47) | ACERENRAB9AKDM4EF2 | |
| SCHEMBL26724818 | 0.87 | ACE (0.47) | ACERENRAB9AKDM4EF2 | |
| SCHEMBL29794202 | 0.86 | ACE (0.51) | ACERENRAB9AKDM4EF2 | |
| SCHEMBL26223783 | 0.86 | DPP4 (0.48) | ACEREN | |
| SCHEMBL19111008 | 0.86 | DPP4 (0.48) | ACEREN | |
| SCHEMBL6782701 | 0.84 | ACE (0.72) | ACEREN | |
| SCHEMBL6782705 | 0.84 | ACE (0.72) | ACEREN | |
| SCHEMBL5742529 | 0.83 | ACE (0.62) | ACERENRAB9AKDM4EF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-11-09 | — | — | US | disclosed |
| WO-2023168367-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| EP-1824876-B1 | PANCREATIC POLYPEPTIDE FAMILY MOTIFS, POLYPEPTIDES AND METHODS COMPRISING THE SAME | AMYLIN PHARMACEUTICALS LLC (US) | 2015-07-29 | — | — | EP | disclosed |
| US-8927687-B2 | Microcrystalline Y receptor agonists | AMYLIN PHARMACEUTICALS, LLC (US) | 2015-01-06 | — | — | US | disclosed |
| US-20130296225-A1 | Microcrystalline Y Receptor Agonists | AMYLIN PHARMACEUTICALS LLC (US) | 2013-11-07 | — | — | US | disclosed |
| EP-2600887-A2 | MICROCRYSTALLINE Y RECEPTOR AGONISTS | Amylin Pharmaceuticals, LLC (US) | 2013-06-12 | — | — | EP | disclosed |
| WO-2012006566-A2 | MICROCRYSTALLINE Y RECEPTOR AGONISTS | AMYLIN PHARMACEUTICALS, INC. (US) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | ACE 485/4885REN 2518/4885RAB9A 2346/4885 |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, GLS2, GLS | ACE 485/4885REN 2518/4885RAB9A 2346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.